STOK vs. JANX, TVTX, AGIO, TARS, APGE, VERA, IRON, SDGR, GLPG, and AAPG
Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Agios Pharmaceuticals (AGIO), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Vera Therapeutics (VERA), Disc Medicine (IRON), Schrödinger (SDGR), Galapagos (GLPG), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
Stoke Therapeutics vs.
Stoke Therapeutics (NASDAQ:STOK) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Janux Therapeutics has lower revenue, but higher earnings than Stoke Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Stoke Therapeutics had 31 more articles in the media than Janux Therapeutics. MarketBeat recorded 41 mentions for Stoke Therapeutics and 10 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.13 beat Stoke Therapeutics' score of 0.74 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Stoke Therapeutics received 74 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 76.13% of users gave Stoke Therapeutics an outperform vote while only 70.97% of users gave Janux Therapeutics an outperform vote.
Stoke Therapeutics currently has a consensus price target of $24.67, suggesting a potential upside of 233.33%. Janux Therapeutics has a consensus price target of $92.44, suggesting a potential upside of 206.92%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Stoke Therapeutics is more favorable than Janux Therapeutics.
75.4% of Janux Therapeutics shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Janux Therapeutics has a net margin of -463.91% compared to Stoke Therapeutics' net margin of -629.90%. Janux Therapeutics' return on equity of -10.47% beat Stoke Therapeutics' return on equity.
Stoke Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.23, suggesting that its share price is 223% more volatile than the S&P 500.
Summary
Janux Therapeutics beats Stoke Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Stoke Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stoke Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:STOK) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy STOK Stock Free STOK Stock Alerts